Re:Cognition Health USA has been awarded the GCSA Clinical Trial Site Certification, making it the first organization to hold this distinction in both the United States and Europe. This certification signifies that the site operates according to the highest global standards in clinical research.
The GCSA (Global Clinical Site Alliance) certification is granted to sites demonstrating excellence in clinical research operations. The assessment, conducted by the International Accrediting Organization for Clinical Research (IAOCR), involves a thorough review and gap analysis to ensure compliance with the GCSA Global Quality Standard for Clinical Research Sites.
Key Areas of Excellence
The GCSA standard evaluates clinical research sites across seven essential areas crucial for conducting world-class clinical trials:
- Feasibility
- Study Start-Up and Initiation
- Patient Engagement
- Study Management, Operations, and Close Down
- Workforce Process Quality
- Site Business Strategy
- Governance
Mostafa Hassan, MBBCH, Director of Clinical Trials, USA at Re:Cognition Health USA, expressed pride in this achievement, stating, "We are thrilled to have achieved the GCSA quality standard and certification – it’s truly a testament to the hard work and dedication of the entire Re:Cognition Health US team. We’re confident that this achievement will further enhance our commitment to excellence in clinical trials and patient care."
Benefits of GCSA Certification
The GCSA quality mark serves as a guarantee to sponsors, CROs, staff, and patients that the research site has undergone independent quality assurance against robust global standards. This certification positions the site as a 'Trusted Global Partner' for the execution of clinical trials, ensuring reliability and adherence to best practices.
